- Home
- IAS vs LQDA Comparison
IAS vs LQDA Comparison
Compare IAS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- LQDA
- Stock Information
- Founded
- IAS 2009
- LQDA 2004
- Country
- IAS United States
- LQDA United States
- Employees
- IAS N/A
- LQDA N/A
- Industry
- IAS Computer Software: Programming Data Processing
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- LQDA Health Care
- Exchange
- IAS Nasdaq
- LQDA Nasdaq
- Market Cap
- IAS 1.3B
- LQDA 1.2B
- IPO Year
- IAS 2021
- LQDA 2018
- Fundamental
- Price
- IAS $8.49
- LQDA $16.46
- Analyst Decision
- IAS Buy
- LQDA Strong Buy
- Analyst Count
- IAS 11
- LQDA 9
- Target Price
- IAS $13.65
- LQDA $27.67
- AVG Volume (30 Days)
- IAS 711.1K
- LQDA 2.1M
- Earning Date
- IAS 08-07-2025
- LQDA 08-06-2025
- Dividend Yield
- IAS N/A
- LQDA N/A
- EPS Growth
- IAS 2607.38
- LQDA N/A
- EPS
- IAS 0.29
- LQDA N/A
- Revenue
- IAS $549,637,000.00
- LQDA $14,144,000.00
- Revenue This Year
- IAS $13.39
- LQDA $189.27
- Revenue Next Year
- IAS $11.41
- LQDA $402.79
- P/E Ratio
- IAS $29.67
- LQDA N/A
- Revenue Growth
- IAS 13.84
- LQDA N/A
- 52 Week Low
- IAS $6.26
- LQDA $8.26
- 52 Week High
- IAS $13.62
- LQDA $19.41
- Technical
- Relative Strength Index (RSI)
- IAS 60.47
- LQDA 63.82
- Support Level
- IAS $7.83
- LQDA $14.04
- Resistance Level
- IAS $8.68
- LQDA $14.67
- Average True Range (ATR)
- IAS 0.20
- LQDA 0.66
- MACD
- IAS 0.03
- LQDA 0.34
- Stochastic Oscillator
- IAS 82.35
- LQDA 98.97
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.